General MedicationsINHALATIONStandard
INBRIJA
LEVODOPA
Standard Dose
42MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview INBRIJA is listed in Drugs@FDA under application 209184 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient LEVODOPA Form and strength POWDER;INHALATION - 42MG Sponsor MERZ Submission history Latest submission status date: 2026-03-31 00:00:00.
Structured Monograph
Clinical summary
Approval overview INBRIJA is listed in Drugs@FDA under application 209184 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient LEVODOPA Form and strength POWDER;INHALATION - 42MG Sponsor MERZ Submission history Latest submission status date: 2026-03-31 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.